Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.

You may also be interested in...

Capsugel CEO Driesen Plots Post-Pfizer Course

Guido Driesen, president and CEO of Capsugel, says the oral dosage technology firm is having a record year after being divested by Pfizer. In an interview, he discusses the firm’s applications for OTC drugs and nutritionals, as well as Capsugel’s international expansion.

Pfizer Will Unload Nutrition Division, Keep Consumer Product Unit

Pfizer will divest or spin off its nutrition unit but the firm will keep its consumer product business and look into future OTC switches.

Reading Into Pfizer's Changes: First Steps For New CEO

Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts